阿曲生坦在已用SGLT2抑制剂的IgA肾病中的疗效与安全性:安慰剂对照交叉试验
该随机双盲安慰剂对照交叉试验纳入54例已接受最大稳定剂量RASi和SGLT2i治疗、UPCR≥0.5 g/d的IgA肾病患者,评估阿曲生坦0.75 mg每日一次与安慰剂的疗效。主要终点第12周UPCR几何均值百分比变化的组间差异为-25.3%(95%CI -36.8至-11.7;P<0.001),安全性良好。
要点
- 在RASi和SGLT2i基础上加用阿曲生坦可进一步降低IgA肾病患者蛋白尿。
- 第12周UPCR几何均值百分比变化的组间差异为-25.3%(95%CI -36.8至-11.7;P<0.001)。
- 安全性良好,无因治疗相关不良事件停药,无死亡。
核心结论
- 阿曲生坦可为已接受RASi和SGLT2i治疗的IgA肾病患者提供有临床意义的蛋白尿下降,且耐受性良好。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,纳入54例IgA肾病患者,eGFR≥30 ml/min/1.73 m²且尿蛋白>0.5 g/d,正在使用最大稳定剂量RASi和SGLT2i。
- 参与者1:1随机分配至AB或BA序列,A为阿曲生坦0.75 mg每日一次,B为匹配安慰剂,两期之间洗脱12周。
主要发现
- 第12周阿曲生坦组与安慰剂组UPCR几何均值百分比变化的差异为-25.3%(95%CI -36.8至-11.7;P<0.001)。
- 第24周(第二治疗期)UPCR的组间差异为-26.4%(95%CI -45.8至-0.0)。
- 发生1例不相关的严重不良事件;液体潴留事件不常见,无需住院;无因治疗相关不良事件停药,无死亡。
临床怎么用
- 对于已接受RASi和SGLT2i治疗但仍有蛋白尿的IgA肾病患者,可考虑加用阿曲生坦以进一步降低蛋白尿。
- 使用阿曲生坦时需关注液体潴留等不良事件,但本研究中未见需住院的液体潴留事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Patients with IgA nephropathy and proteinuria are at risk of kidney failure despite use of guideline-recommended renin-angiotensin system and sodium-glucose cotransporter 2 (SGLT2) inhibition. Atrasentan reduces proteinuria in IgA nephropathy, but its efficacy as adjunct to renin-angiotensin system and SGLT2 inhibition has not been rigorously tested. Atrasentan provided a clinically meaningful reduction in proteinuria in adults with IgA nephropathy treated with renin-angiotensin system and SGLT2 inhibitors. BACKGROUND: Atrasentan, a highly selective endothelin-A receptor antagonist, is approved for proteinuria reduction in adults with IgA nephropathy. Renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are guideline recommended, yet the additional benefit of atrasentan has not been rigorously determined. METHODS: We performed a randomized, double-blind, placebo-controlled crossover study of atrasentan in adults with IgA nephropathy, eGFR ≥30 ml/min per 1.73 m 2 , and urinary protein >0.5 g/d while on maximal, stable RASi and SGLT2i. Participants were randomized 1:1 to either sequence AB or sequence BA (0.75 mg atrasentan [A] once daily during period 1 and matching placebo [B] during period 2, or vice versa), with a 12-week washout period in between. The primary end point was the change in urinary protein-to-creatinine ratio (UPCR) to week 12. The secondary end point was the change in UPCR to week 24. Safety end points included the type, incidence, severity, seriousness, and relatedness of adverse events (AEs). RESULTS: We recruited 54 participants with mean age 48 years (SD 12), 43% female, mean (SD) eGFR 63 (22) ml/min per 1.73 m 2 , and median UPCR 1.0 g/g (Q1-Q3, 0.7-1.4). Treatment with atrasentan versus placebo resulted in a difference in geometric mean percentage change in UPCR at week 12 of -25.3% (95% confidence interval, -36.8 to -11.7; P < 0.001). The treatment difference in UPCR between atrasentan versus placebo during treatment period 2 at week 24 was -26.4% (95% confidence interval, -45.8 to -0.0). There was one unrelated serious adverse event. Fluid retention events were uncommon, and none required hospitalization. There were no study drug discontinuations due to treatment-related adverse events and no deaths. CONCLUSIONS: Atrasentan provided a clinically meaningful reduction in proteinuria in adults with IgA nephropathy and proteinuria ≥0.5 g/d treated with RASi and SGLT2i therapy. Atrasentan was well tolerated, and no new safety signals emerged. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT05834738 .
引用
- Heerspink HJL, Noronha IL, Górriz JL, et al. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2026. PMID: 41904616. doi:10.1681/ASN.0000001076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。